Literature DB >> 29483142

STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.

Cristina Maranto1,2, Vindhya Udhane1,2, David T Hoang3, Lei Gu3, Vitali Alexeev4, Kareem Malas1,2, Karmel Cardenas1,2, Jonathan R Brody5, Ulrich Rodeck4, Carmen Bergom6, Ken A Iczkowski1, Ken Jacobsohn7, William See7, Sara M Schmitt1,2, Marja T Nevalainen8,2.   

Abstract

Purpose: The standard treatment for organ-confined prostate cancer is surgery or radiation, and locally advanced prostate cancer is typically treated with radiotherapy alone or in combination with androgen deprivation therapy. Here, we investigated whether Stat5a/b participates in regulation of double-strand DNA break repair in prostate cancer, and whether Stat5 inhibition may provide a novel strategy to sensitize prostate cancer to radiotherapy.Experimental Design: Stat5a/b regulation of DNA repair in prostate cancer was evaluated by comet and clonogenic survival assays, followed by assays specific to homologous recombination (HR) DNA repair and nonhomologous end joining (NHEJ) DNA repair. For HR DNA repair, Stat5a/b regulation of Rad51 and the mechanisms underlying the regulation were investigated in prostate cancer cells, xenograft tumors, and patient-derived prostate cancers ex vivo in 3D explant cultures. Stat5a/b induction of Rad51 and HR DNA repair and responsiveness to radiation were evaluated in vivo in mice bearing prostate cancer xenograft tumors.
Results: Stat5a/b is critical for Rad51 expression in prostate cancer via Jak2-dependent mechanisms by inducing Rad51 mRNA levels. Consistent with this, genetic knockdown of Stat5a/b suppressed HR DNA repair while not affecting NHEJ DNA repair. Pharmacologic Stat5a/b inhibition potently sensitized prostate cancer cell lines and prostate cancer tumors to radiation, while not inducing radiation sensitivity in the neighboring tissues.Conclusions: This work introduces a novel concept of a pivotal role of Jak2-Stat5a/b signaling for Rad51 expression and HR DNA repair in prostate cancer. Inhibition of Jak2-Stat5a/b signaling sensitizes prostate cancer to radiation and, therefore, may provide an adjuvant therapy for radiation to reduce radiation-induced damage to the neighboring tissues. Clin Cancer Res; 24(8); 1917-31. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Year:  2018        PMID: 29483142      PMCID: PMC6036914          DOI: 10.1158/1078-0432.CCR-17-2768

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

Review 1.  Survival and Complications Following Surgery and Radiation for Localized Prostate Cancer: An International Collaborative Review.

Authors:  Christopher J D Wallis; Adam Glaser; Jim C Hu; Hartwig Huland; Nathan Lawrentschuk; Daniel Moon; Declan G Murphy; Paul L Nguyen; Matthew J Resnick; Robert K Nam
Journal:  Eur Urol       Date:  2017-06-11       Impact factor: 20.096

Review 2.  Moonlighting at replication forks - a new life for homologous recombination proteins BRCA1, BRCA2 and RAD51.

Authors:  Arun Mouli Kolinjivadi; Vincenzo Sannino; Anna de Antoni; Hervé Técher; Giorgio Baldi; Vincenzo Costanzo
Journal:  FEBS Lett       Date:  2017-01-30       Impact factor: 4.124

Review 3.  DNA Repair in Prostate Cancer: Biology and Clinical Implications.

Authors:  Joaquin Mateo; Gunther Boysen; Christopher E Barbieri; Helen E Bryant; Elena Castro; Pete S Nelson; David Olmos; Colin C Pritchard; Mark A Rubin; Johann S de Bono
Journal:  Eur Urol       Date:  2016-08-31       Impact factor: 20.096

4.  Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia.

Authors:  Zhiyong Liao; Lei Gu; Jenny Vergalli; Samanta A Mariani; Marco De Dominici; Ravi K Lokareddy; Ayush Dagvadorj; Puranik Purushottamachar; Peter A McCue; Edouard Trabulsi; Costas D Lallas; Shilpa Gupta; Elyse Ellsworth; Shauna Blackmon; Adam Ertel; Paolo Fortina; Benjamin Leiby; Guanjun Xia; Hallgeir Rui; David T Hoang; Leonard G Gomella; Gino Cingolani; Vincent Njar; Nagarajan Pattabiraman; Bruno Calabretta; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2015-05-29       Impact factor: 6.261

5.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

Authors:  K S McCarty; L S Miller; E B Cox; J Konrath; K S McCarty
Journal:  Arch Pathol Lab Med       Date:  1985-08       Impact factor: 5.534

6.  Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade.

Authors:  Hongzhen Li; Tommi J Ahonen; Kalle Alanen; Jianwu Xie; Matthew J LeBaron; Thomas G Pretlow; Erica L Ealley; Ying Zhang; Martti Nurmi; Baljit Singh; Paula M Martikainen; Marja T Nevalainen
Journal:  Cancer Res       Date:  2004-07-15       Impact factor: 12.701

7.  Hormone regulation of human prostate in organ culture.

Authors:  M T Nevalainen; P L Härkönen; E M Valve; W Ping; M Nurmi; P M Martikainen
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

8.  Use of the Rad51 promoter for targeted anti-cancer therapy.

Authors:  Christopher M Hine; Andrei Seluanov; Vera Gorbunova
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-23       Impact factor: 11.205

9.  Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo.

Authors:  Ayush Dagvadorj; Robert A Kirken; Benjamin Leiby; James Karras; Marja T Nevalainen
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

Review 10.  DNA repair pathways as targets for cancer therapy.

Authors:  Thomas Helleday; Eva Petermann; Cecilia Lundin; Ben Hodgson; Ricky A Sharma
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716

View more
  18 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

2.  Prostate cancer: Radiosensitized by STAT5 blockade.

Authors:  Clemens Thoma
Journal:  Nat Rev Urol       Date:  2018-03-20       Impact factor: 14.432

3.  LINC00200 contributes to the chemoresistance to oxaliplatin of gastric cancer cells via regulating E2F1/RAD51 axis.

Authors:  Mengxin Lin; Meifang Xu; Zongbin Xu; Zongqi Weng; Bingqiang Lin; Yanqin Lan; Qing Liu; Xiaoyan Lin; Jie Pan
Journal:  Hum Cell       Date:  2021-04-06       Impact factor: 4.174

4.  The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521.

Authors:  William A Hall; Theodore G Karrison; Seth A Rosenthal; Mahul B Amin; Leonard G Gomella; James A Purdy; A Oliver Sartor; Jeff M Michalski; Mark G Garzotto; Carmen Bergom; Ashesh B Jani; Colleen A F Lawton; Jeffry P Simko; Joan K Moore; Elizabeth M Gore; W Robert Lee; Paul L Nguyen; Brita L Danielson; Howard M Sandler; Felix Y Feng
Journal:  Int J Radiat Oncol Biol Phys       Date:  2022-06-05       Impact factor: 8.013

5.  Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer.

Authors:  Dimple Chakravarty; Parita Ratnani; Li Huang; Zachary Dovey; Stanislaw Sobotka; Roy Berryhill; Harri Merisaari; Majd Al Shaarani; Richa Rai; Ivan Jambor; Kamlesh K Yadav; Sandeep Mittan; Sneha Parekh; Julia Kodysh; Vinayak Wagaskar; Rachel Brody; Carlos Cordon-Cardo; Dmitry Rykunov; Boris Reva; Elai Davicioni; Peter Wiklund; Nina Bhardwaj; Sujit S Nair; Ashutosh K Tewari
Journal:  Cancers (Basel)       Date:  2022-05-31       Impact factor: 6.575

6.  Relevance of humanized three-dimensional tumor tissue models: a descriptive systematic literature review.

Authors:  D Contartese; Francesca Salamanna; F Veronesi; M Fini
Journal:  Cell Mol Life Sci       Date:  2020-04-13       Impact factor: 9.261

7.  Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors.

Authors:  Vindhya Udhane; Cristina Maranto; David T Hoang; Lei Gu; Andrew Erickson; Savita Devi; Pooja G Talati; Anjishnu Banerjee; Kenneth A Iczkowski; Kenneth Jacobsohn; William A See; Tuomas Mirtti; Deepak Kilari; Marja T Nevalainen
Journal:  Mol Cancer Ther       Date:  2019-09-23       Impact factor: 6.261

8.  Interleukin-6 Function and Targeting in Prostate Cancer.

Authors:  Zoran Culig
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  CD81 Enhances Radioresistance of Glioblastoma by Promoting Nuclear Translocation of Rad51.

Authors:  Wang Zheng; Qianping Chen; Hongxia Liu; Songling Hu; Yuchuan Zhou; Yang Bai; Jianghong Zhang; Yan Pan; Chunlin Shao
Journal:  Cancers (Basel)       Date:  2021-04-21       Impact factor: 6.639

Review 10.  Epigenetic mechanisms underlying prostate cancer radioresistance.

Authors:  Catarina Macedo-Silva; Rosaria Benedetti; Fortunato Ciardiello; Salvatore Cappabianca; Carmen Jerónimo; Lucia Altucci
Journal:  Clin Epigenetics       Date:  2021-06-08       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.